Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Illumina Inc ILMN

Technology Scientific & Technical Instruments
Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.


NDAQ:ILMN - Post by User

Illumina Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(161)
•••
Post by R_J_on Sep 01, 2020 8:32am
125 Views
Post# 31485263

End of Month - August 2020

End of Month - August 2020End of the Month Report for August 2020 for Illumina Inc.
-
ILMN closed on 08/31/2020 at US$ 357.22
ILMN closed on 01731/2020 at US$ 382.16
-
This is a 6.5% loss, a US$ 24.94 loss, for August
-
S&P 500 Index, @ 3500.3 gained 7.0% in August. [13.5% above its MA(200) @ 3085.1]
-
Two Hundred Day Moving Average [MA(200)] stuff.
ILMN's  MA(200) ended August at US$324.52
ILMN is now 10.1% above its MA(200).
-
News Releases on the ILMN Website in August
-
Aug 25, 2020     
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
-
Aug 7, 2020     
Illumina to Webcast Upcoming Investor Conference Presentation
-
Aug 6, 2020     
Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome
-
Aug 6, 2020     
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020
-
Who is in charge?
Francis A. DeSouza, CEO
-
RJ


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities